接受甲氨蝶呤和环孢素联合治疗的银屑病患者的无癌生存期。
Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination.
作者信息
Aydin Fatma, Yuksel Esra Pancar, Senturk Nilgun, Canturk Tayyar, Turanli Ahmet Yasar
机构信息
Department of Dermatology, Ondokuz Mayis University , Samsun , Turkey.
出版信息
Cutan Ocul Toxicol. 2014 Sep;33(3):181-3. doi: 10.3109/15569527.2013.825805. Epub 2013 Aug 15.
CONTEXT
Combination of methotrexate and cyclosporine was used and reported to be effective for recalcitrant psoriasis patients. Also each agent is accused for development of malignancies.
OBJECTIVE
To evaluate the cancer-free survival of psoriasis patients who received methotrexate and cyclosporine treatment at the same time.
METHODS
Psoriasis patients who had been treated with combination of cyclosporine and methotrexate between March 2000 and April 2005 were questioned in 2011. A diagnosis of new cancer during follow-up period was asked and also each patient was evaluated by a questionnaire.
RESULTS
Seventeen psoriasis patients were not treated due to a diagnosis of new cancer during the follow-up period. Also none of them complained of possible symptoms of skin or lymphoproliferative malignancies. The median follow-up time was 76 months.
CONCLUSION
Psoriasis patients who had been treated with methotrexate and cyclosporine combination did not report a detected malignant disease.
背景
甲氨蝶呤和环孢素联合使用，据报道对顽固性银屑病患者有效。此外，每种药物都被指控会引发恶性肿瘤。
目的
评估同时接受甲氨蝶呤和环孢素治疗的银屑病患者的无癌生存率。
方法
2011年对2000年3月至2005年4月期间接受环孢素和甲氨蝶呤联合治疗的银屑病患者进行了询问。询问了随访期间是否诊断出新发癌症，并且通过问卷调查对每位患者进行了评估。
结果
17例银屑病患者在随访期间因诊断出新发癌症而未接受治疗。此外，他们中没有人抱怨有皮肤或淋巴增殖性恶性肿瘤的可能症状。中位随访时间为76个月。
结论
接受甲氨蝶呤和环孢素联合治疗的银屑病患者未报告检测到恶性疾病。
Zotero 插件